Leerink Partnrs Brokers Decrease Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Leerink Partnrs lowered their FY2025 EPS estimates for shares of Axsome Therapeutics in a report issued on Monday, November 3rd. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($3.86) per share for the year, down from their prior estimate of ($3.33). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($0.87) EPS and FY2026 earnings at $0.35 EPS.

AXSM has been the subject of a number of other reports. Needham & Company LLC restated a “buy” rating and issued a $154.00 price objective on shares of Axsome Therapeutics in a report on Tuesday. B. Riley began coverage on shares of Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 target price on the stock. Morgan Stanley upped their price target on shares of Axsome Therapeutics from $194.00 to $196.00 and gave the company an “overweight” rating in a report on Tuesday. Guggenheim upped their price target on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Royal Bank Of Canada upped their price target on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $180.75.

Axsome Therapeutics Trading Up 0.6%

Shares of AXSM opened at $135.69 on Thursday. The firm has a market cap of $6.77 billion, a price-to-earnings ratio of -26.76 and a beta of 0.50. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. Axsome Therapeutics has a fifty-two week low of $75.56 and a fifty-two week high of $139.13. The firm has a 50 day moving average price of $124.02 and a 200-day moving average price of $113.19.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The business had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The business’s revenue for the quarter was up 63.2% on a year-over-year basis.

Insider Activity

In other news, COO Mark L. Jacobson sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Herriot Tabuteau sold 21,775 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $134.49, for a total transaction of $2,928,519.75. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $972,228.21. This represents a 75.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 407,271 shares of company stock valued at $50,640,415. Corporate insiders own 22.30% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AXSM. Norges Bank purchased a new stake in shares of Axsome Therapeutics in the 2nd quarter worth about $48,889,000. Nuveen LLC bought a new position in shares of Axsome Therapeutics in the 1st quarter worth about $48,185,000. Adage Capital Partners GP L.L.C. increased its stake in shares of Axsome Therapeutics by 831.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock worth $46,662,000 after acquiring an additional 399,000 shares in the last quarter. Hood River Capital Management LLC bought a new position in shares of Axsome Therapeutics in the 2nd quarter worth about $38,740,000. Finally, 1832 Asset Management L.P. bought a new position in shares of Axsome Therapeutics in the 1st quarter worth about $42,360,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.